Impact of preexisting type 2 diabetes mellitus and antidiabetic drugs on all-cause and cause-specific mortality among Medicaid-insured women diagnosed with breast cancer

• Published in: Cancer epidemiology 2020-06, Vol.66, p.101710-101710, Article 101710
• Main Authors: Lawrence, Wayne R., Hosler, Akiko S., Gates Kuliszewski, Margaret, Leinung, Matthew C., Zhang, Xiuling, Schymura, Maria J., Boscoe, Francis P.
• Format: Article
• Language: English
• Subjects: Age; Antidiabetics; Breast cancer; Breast Neoplasms - complications; Breast Neoplasms - mortality; Cancer; Cancer registry; Cancer therapies; Cardiovascular; Cardiovascular disease; Cause of Death - trends; Chronology; Confidence intervals; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - epidemiology; Diagnosis; Epidemiology; Female; Glucose-lowering drugs; Government programs; Health hazards; Health risk assessment; Humans; Hypoglycemic Agents - pharmacology; Hypoglycemic Agents - therapeutic use; Insulin; Medicaid; Medicaid - standards; Menopause; Metformin; Middle Aged; Minority & ethnic groups; Mortality; Post-menopause; Statistical analysis; Subgroups; Sulfonylurea; United States
• ISSN: 1877-7821; 1877-783X
• DOI: 10.1016/j.canep.2020.101710

•Among women with breast cancer, those with type 2 diabetes had higher mortality hazard than nondiabetics.•Women prescribed sulfonylurea or insulin had an elevated mortality hazard compared to women prescribed metformin.•Among women 50 years of age and older with breast cancer, those with type 2 diabetes had a 47% higher mortality hazard. We investigated the influence preexisting type 2 diabetes mellitus (T2DM) and antidiabetic drugs have on all-cause and cause-specific mortality among Medicaid-insured women diagnosed with breast cancer. 9221 women aged